| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| 500g |
|
||
| Other Sizes |
| Targets |
4,6-Dichloro-2-methylpyrimidine (1780-26-3) does not have a defined biological target as it is primarily a synthetic intermediate and chemical building block rather than a therapeutic agent. The compound is used to synthesize more complex pharmaceuticals including Dasatinib, which targets multiple tyrosine kinases including BCR-ABL, Src family kinases (Src, Lck, Yes, Fyn), c-KIT, PDGFR, and EphA2. However, the pyrimidine intermediate itself lacks intrinsic pharmacological activity and serves purely as a molecular scaffold for subsequent chemical transformations to introduce functional groups conferring target binding properties.
|
|---|---|
| ln Vitro |
Not applicable for 4,6-Dichloro-2-methylpyrimidine (1780-26-3) as it is a synthetic intermediate without reported biological activity. The compound is used in chemical synthesis as a building block for pharmaceutical production, particularly for the tyrosine kinase inhibitor Dasatinib and its derivatives. No IC50, EC50, or other potency values have been reported for this substance in the context of target-based assays. Its primary role is as a chemically reactive intermediate enabling nucleophilic aromatic substitution reactions to incorporate various amine substituents at the chlorinated positions.
|
| ln Vivo |
Not applicable for 4,6-Dichloro-2-methylpyrimidine (1780-26-3) as it is a synthetic intermediate without documented in vivo biological activity. The compound is intended for chemical synthesis rather than pharmacological evaluation in animal models. It does not possess intrinsic therapeutic properties as a standalone agent. Any in vivo activity would be associated with the final drug compounds synthesized from this intermediate (such as Dasatinib), not with the precursor itself. The compound is not typically administered to animals for efficacy studies.
|
| Enzyme Assay |
Not applicable for 4,6-Dichloro-2-methylpyrimidine (1780-26-3) as it is a synthetic intermediate without reported receptor binding properties. For general organic chemistry applications, no protein or receptor binding assays have been reported. Standard analytical characterization for this compound includes NMR spectroscopy, GC/HPLC analysis for purity determination, and mass spectrometry for structural confirmation. These methods are used for quality control and chemical identification, not for biological binding assessments. The compound‘s chloro groups are reactive sites for further chemical transformations rather than pharmacophores for receptor interactions.
|
| Cell Assay |
Not applicable for 4,6-Dichloro-2-methylpyrimidine (1780-26-3) as it is a synthetic intermediate without documented cell-based activity. This compound is not typically used in cell culture experiments as a pharmacologically active agent. Its primary applications are in organic synthesis as a starting material for drug manufacturing, particularly for Dasatinib. It would be considered a chemical intermediate, not a test article for cell-based efficacy assays. Standard practice involves converting this intermediate into final APIs before biological testing.
|
| Animal Protocol |
Not applicable for 4,6-Dichloro-2-methylpyrimidine (1780-26-3) as it is a synthetic intermediate without documented in vivo animal study protocols. The compound is used as a chemical precursor rather than as a test article for animal efficacy studies. Any animal studies involving this compound would be for toxicological safety assessment of the chemical itself, not for therapeutic efficacy evaluation. Standard OECD guidelines for chemical safety testing could apply, but no specific protocols are reported in the available literature for this compound. The compound is typically further transformed into APIs like Dasatinib before animal studies.
|
| ADME/Pharmacokinetics |
Not applicable for 4,6-Dichloro-2-methylpyrimidine (1780-26-3) as it is a synthetic intermediate without reported pharmacokinetic studies. The compound is not intended for systemic drug delivery. For chemical safety assessment, the compound has predicted physicochemical properties including XLogP of 2.5, zero hydrogen bond donors, two hydrogen bond acceptors, and zero rotatable bonds, indicating moderate lipophilicity and low water solubility. No formal PK data in humans or animals have been reported. The compound is used primarily as a chemical intermediate in pharmaceutical manufacturing.
|
| Toxicity/Toxicokinetics |
Toxicity data for 4,6-Dichloro-2-methylpyrimidine (1780-26-3) are not widely reported in the available literature. The compound is classified as a combustible solid (Class 11) with a flash point of >97degC (208degF). Safety classifications include Aquatic Chronic 2 (H411 - Toxic to aquatic life with long-lasting effects) and Skin Sensitization 1 (H317 - May cause an allergic skin reaction). The compound may cause skin and eye irritation upon contact. Standard safety precautions include storage in a cool, dry, well-ventilated area away from ignition sources, use of appropriate personal protective equipment (chemical-resistant gloves, safety goggles, lab coat), and avoidance of dust formation. Environmental release should be prevented. In case of fire, use water spray, dry chemical, foam, or carbon dioxide.
|
| References | |
| Additional Infomation |
4,6-Dichloro-2-methylpyrimidine (1780-26-3) has a molecular formula of C5H4Cl2N2 and molecular weight of 163.00 g/mol. Its IUPAC name is 4,6-dichloro-2-methylpyrimidine. Additional synonyms include 2-methyl-4,6-dichloropyrimidine and pyrimidine, 4,6-dichloro-2-methyl-. The compound appears as a white to light yellow powder to crystal. Melting point range: 41-48degC (with variations: 41.5-45.5degC, 44.0-48.0degC). Flash point: >97degC (208degF). Purity: typically >95-98% by GC. Storage conditions: inert atmosphere, room temperature, in a cool, dry place away from incompatible materials. The compound is moisture-sensitive and should be kept sealed. It is classified as a hazardous substance with environmental and skin sensitization warnings.
|
| Molecular Formula |
C5H4CL2N2
|
|---|---|
| Molecular Weight |
163.00
|
| Exact Mass |
161.975
|
| CAS # |
1780-26-3
|
| PubChem CID |
234997
|
| Appearance |
Off-white to yellow solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
89
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NC(=CC(=N1)Cl)Cl
|
| InChi Key |
FIMUTBLUWQGTIJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H4Cl2N2/c1-3-8-4(6)2-5(7)9-3/h2H,1H3
|
| Chemical Name |
4,6-dichloro-2-methylpyrimidine
|
| Synonyms |
2-Methyl-4,6-dichloropyrimidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1350 mL | 30.6748 mL | 61.3497 mL | |
| 5 mM | 1.2270 mL | 6.1350 mL | 12.2699 mL | |
| 10 mM | 0.6135 mL | 3.0675 mL | 6.1350 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
